Navigation Links
Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
Date:1/10/2012

chizophrenia, bipolar disease and depression) as well as all other antihistamines, opioids, alpha and beta blockers, serotonergics and dopaminergics. 

The industry focuses its GPCR drug discovery efforts mostly on non-sensory GPCRs. Of the 363 total non-sensory GPCRs, approximately 240 have known ligands (molecules that bind the receptors) with nearly half of those targeted either by marketed drugs (46 GPCRs) or by drugs in development (about 70 GPCRs). There are approximately 120 GPCRs with no known ligands, which are termed "orphan GPCRs." Without a known ligand, drug development for a given receptor is extremely difficult.

Omeros uses its proprietary high-throughput CRA to identify small-molecule agonists and antagonists for orphan GPCRs, unlocking them to drug development. Omeros believes that it is the first to possess the capability to unlock orphan GPCRs in high-throughput, and that currently there is no other comparable technology. Unlocking these receptors could lead to the development of drugs that act at these new targets. There is a broad range of indications linked to orphan GPCRs including cardiovascular disease, asthma, diabetes, pain, obesity, Alzheimer's disease, Parkinson's disease, multiple sclerosis, schizophrenia, learning and cognitive disorders, autism, osteoporosis, osteoarthritis and several forms of cancer.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a l
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
2. Omeros to Present at Rodman and Renshaw 13th Annual Healthcare Conference
3. Omeros to Present at Two Upcoming Conferences
4. Omeros to Present at Future Leaders in the Biotech Industry Conference
5. Omeros to Present at Needham Healthcare Conference
6. Omeros Corporation Awarded $1.7 Million in Grants Under the Qualifying Therapeutic Discovery Project Program
7. Omeros Announces Additional Support from the National Institute on Drug Abuse for Clinical Studies in Addiction Program
8. Omeros Secures $40 Million Committed Equity Financing Facility
9. Omeros To Webcast Presentation at Ninth Annual Needham Healthcare Conference
10. Omeros to Webcast Presentation at Deutsche Bank 35th Annual Health Care Conference
11. Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... July 14, 2014 Throughout this ... across the clinical trials space, representing 38 countries ... series entitled “Optimizing Patient Participation in Clinical Trials. ... off with internationally renowned R&D expert, Ken Getz, ... on Reinventing Drug Development through Patient Centricity. , ...
(Date:7/14/2014)... Mass. , July 14, 2014 Minerva ... the development of new therapies to treat neuropsychiatric diseases ... has been appointed vice president of finance and ... Mr. Ahlholm is a senior executive with more than ... at technology and life science companies. His background includes ...
(Date:7/14/2014)... Mateo, CA (PRWEB) July 14, 2014 ... CONNECT patient registry platform, announced that three ... muscular dystrophies; the Phelan-McDermid Syndrome International Registry; ... Nephrotic Syndrome—have been awarded contracts by the ... of the creation of a new health ...
(Date:7/13/2014)... R.I. (Brown University) -- The discovery 30 years ago ... an explosion of nanotechnology research. Now, there appears to ... from Brown University, Shanxi University and Tsinghua University in ... atoms forms a hollow molecular cage similar to a ... boron cage structurepreviously only a matter of speculationdoes indeed ...
Breaking Biology Technology:Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 2Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 3Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 4Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 5Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer 2PatientCrossroads Fuels Development of New National Clinical Research Network 2PatientCrossroads Fuels Development of New National Clinical Research Network 3Researchers discover boron 'buckyball' 2Researchers discover boron 'buckyball' 3
... (the,"Company") (OTC Bulletin Board: TBIO) today announced financial results ... results are,presented in the tables that follow. Second ... of $0.2 million or $0.00 per share,for the second ... of $0.4 million or,$0.01 per share for the second ...
... Mass., Aug. 14 Avitar, Inc. (OTC,Bulletin Board: AVTI) ... ended June 30, 2007. For the quarter ended ... operations compared to $1,202,000 from continuing,operations for the quarter ... amounted to $597,000 versus $696,000. The net income,was $301,000, ...
... -- China Medical,Technologies, Inc. (the "Company") (Nasdaq: ... develops, manufactures and markets advanced in-,vitro diagnostic products ... announced that it will participate in the Morgan,Stanley,s ... Kong Date: August 21, 2007 China ...
Cached Biology Technology:Transgenomic, Inc. Reports Second Quarter 2007 Results 2Transgenomic, Inc. Reports Second Quarter 2007 Results 3Transgenomic, Inc. Reports Second Quarter 2007 Results 4Transgenomic, Inc. Reports Second Quarter 2007 Results 5Transgenomic, Inc. Reports Second Quarter 2007 Results 6Transgenomic, Inc. Reports Second Quarter 2007 Results 7Transgenomic, Inc. Reports Second Quarter 2007 Results 8Avitar Reports Third Quarter Financial Results for Fiscal 2007 2Avitar Reports Third Quarter Financial Results for Fiscal 2007 3Avitar Reports Third Quarter Financial Results for Fiscal 2007 4
(Date:7/14/2014)... have shown how the main psychoactive ingredient in cannabis ... Research published today reveals the existence of previously unknown ... in shrinking tumours. , It is hoped that ... anti-cancer properties. , The research was co-led ... used samples of human breast cancer cells to induce ...
(Date:7/13/2014)... of more effective treatments for cachexia, a profound wasting ... all cancer patients, raising their risk of death, according ... have been tried to reverse the condition, which may ... treatments, but none have had great success. , Scientists ... Nature , led by Bruce Spiegelman, PhD, demonstrated ...
(Date:7/11/2014)... awarded Michael F. Holick, PhD, MD, of Boston University ... Avioli Award. Holick, a professor of medicine, physiology and ... understanding of vitamin D and its role in disease ... the American Society for Bone and Mineral Research (ASBMR) ... It is named for ASBMR,s first president and founding ...
Breaking Biology News(10 mins):UEA research reveals how cannabis compound could slow tumour growth 2Antibody halts cancer-related wasting condition 2Antibody halts cancer-related wasting condition 3BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2
... a drink problem, there is a greater risk that you ... from the Sahlgrenska Academy, at the University of Gothenburg, Sweden. ... 50% more likely to have a drink problem in the ... new light on this link. Carried out by researcher Anna ...
... LAWRENCE University of Kansas scientists have found new evidence ... (LCPUFA) are good for developing brains and hearts. In ... of four formulas from birth to 12 months; three with ... formula with no LCPUFA, and tested at four, six and ...
... our understanding of genetics and biological processes in all animals, ... of animals, scientists are still finding the fruit fly to ... the University of Rochester. The latest revelation has to ... fruit flies. It was widely accepted that all X chromosomes ...
Cached Biology News:New thinking on regulation of sex chromosomes in fruit flies 2
... These handy dispensers save space and ... and other garb. They are the ... parts used in labs, processing and ... charges and the particles they attract. ...
... 2 NaO 7 S 2 Formula Weight: ... Identity: By IR epsilon max (615 nm, ... equal to 60 x 10 3 Loss ... lambda max (H 2 O solution): ...
...
... research-grade spectrofluorometer with a minimum 1 nm ... 200 or greater for the Raman band ... to keep in mind in order to ... titration, or anisotropic measurements. ,The FP-6500 is ...
Biology Products: